Abstract:Background Daratumumab (DARA), a human IgGκ monoclonal antibody targeting CD38, is approved by the FDA and EMA for the treatment of newly diagnosed multiple myeloma (NDMM) in combination with standard-of-care regimens. DARA in combination with VMP (D-VMP) was approved based on results of the phase 3 ALCYONE trial. The phase 3 OCTANS study investigated the efficacy and safety of D-VMP in Asian NDMM patients (NCT03217812). Here, we present a subgroup analysis of D-VMP in Chinese patients in OCTANS. Methods Asian patients with NDMM who were ineligible for ASCT were randomized (2:1) to D-VMP or VMP. Patients received 9 (42-day) cycles of bortezomib (1.3 mg/m2 SC) twice weekly in Cycle 1 (Weeks 1, 2, 4, 5) then once weekly (QW) in Cycles 2-9 (Weeks 1, 2, 4, 5); melphalan (9 mg/m2 PO) and prednisone (60 mg/m2 PO) once daily on Days 1-4 of each cycle. DARA (16 mg/kg IV) was administered to patients in the D-VMP arm QW in Cycle 1, Q3W in Cycles 2-9, and Q4W thereafter until disease progression or unacceptable toxicity. The primary endpoint was the very good partial response or better (≥VGPR) rate. Key secondary endpoints included progression-free survival (PFS), overall response rate (ORR), and safety. Minimal residual disease (MRD) negativity (10–5) rate was an exploratory endpoint. Results A total of 167 Chinese patients were enrolled (D-VMP [n=114]; VMP [n=53]). Baseline characteristics were balanced between arms; median age was 69 (range, 57-81) years and 35 (21.0%) patients had high-risk cytogenetics. At the time of data analysis (clinical cutoff 2 July 2020), 31 (27.2%) patients in the D-VMP arm had discontinued treatment vs 19 (36.5%) patients in the VMP arm. At a median follow-up of 12.3 (range, 0-29.3) months for the overall study population, ≥VGPR rate was significantly improved with D-VMP vs VMP (74.6% vs 45.3%; odds ratio, 3.51; 95% CI 1.76-7.00; P=0.0003). ORR was 90.4% with D-VMP and 83.0% with VMP. Patients in the D-VMP arm achieved significantly higher MRD-negativity rates (29.8% vs 5.7%; P=0.0003). Median PFS was not reached with D-VMP vs 18.2 months with VMP (HR 0.41; 95% CI 0.21-0.78; P=0.0049); the estimated 12-month PFS rate was 83.4% vs 62.6%, respectively. The most frequent (≥10%) grade 3/4 treatment-emergent adverse events (TEAEs) for the D-VMP/VMP arms were thrombocytopenia (47.4%/44.2%), leukopenia (39.5%/48.1%), lymphopenia (38.6%/28.8%), neutropenia (37.7%/51.9%), pneumonia (32.5%/17.3%), anemia (26.3%/25.0%), hypokalemia (16.7%/3.8%), and hypertension (10.5%/11.5%). Infusion-related reactions occurred in 36 (31.6%) patients, the majority of which were mild. A total of 5 TEAE-related deaths (D-VMP, n=3; VMP, n=2) were reported. Conclusion The addition of DARA to VMP significantly improved efficacy in Chinese NDMM patients and showed a safety profile consistent with the global ALCYONE trial. No new safety concerns were identified. These data support the use of D-VMP for the treatment of Chinese NDMM patients. Daratumumab (DARA), a human IgGκ monoclonal antibody targeting CD38, is approved by the FDA and EMA for the treatment of newly diagnosed multiple myeloma (NDMM) in combination with standard-of-care regimens. DARA in combination with VMP (D-VMP) was approved based on results of the phase 3 ALCYONE trial. The phase 3 OCTANS study investigated the efficacy and safety of D-VMP in Asian NDMM patients (NCT03217812). Here, we present a subgroup analysis of D-VMP in Chinese patients in OCTANS. Asian patients with NDMM who were ineligible for ASCT were randomized (2:1) to D-VMP or VMP. Patients received 9 (42-day) cycles of bortezomib (1.3 mg/m2 SC) twice weekly in Cycle 1 (Weeks 1, 2, 4, 5) then once weekly (QW) in Cycles 2-9 (Weeks 1, 2, 4, 5); melphalan (9 mg/m2 PO) and prednisone (60 mg/m2 PO) once daily on Days 1-4 of each cycle. DARA (16 mg/kg IV) was administered to patients in the D-VMP arm QW in Cycle 1, Q3W in Cycles 2-9, and Q4W thereafter until disease progression or unacceptable toxicity. The primary endpoint was the very good partial response or better (≥VGPR) rate. Key secondary endpoints included progression-free survival (PFS), overall response rate (ORR), and safety. Minimal residual disease (MRD) negativity (10–5) rate was an exploratory endpoint. A total of 167 Chinese patients were enrolled (D-VMP [n=114]; VMP [n=53]). Baseline characteristics were balanced between arms; median age was 69 (range, 57-81) years and 35 (21.0%) patients had high-risk cytogenetics. At the time of data analysis (clinical cutoff 2 July 2020), 31 (27.2%) patients in the D-VMP arm had discontinued treatment vs 19 (36.5%) patients in the VMP arm. At a median follow-up of 12.3 (range, 0-29.3) months for the overall study population, ≥VGPR rate was significantly improved with D-VMP vs VMP (74.6% vs 45.3%; odds ratio, 3.51; 95% CI 1.76-7.00; P=0.0003). ORR was 90.4% with D-VMP and 83.0% with VMP. Patients in the D-VMP arm achieved significantly higher MRD-negativity rates (29.8% vs 5.7%; P=0.0003). Median PFS was not reached with D-VMP vs 18.2 months with VMP (HR 0.41; 95% CI 0.21-0.78; P=0.0049); the estimated 12-month PFS rate was 83.4% vs 62.6%, respectively. The most frequent (≥10%) grade 3/4 treatment-emergent adverse events (TEAEs) for the D-VMP/VMP arms were thrombocytopenia (47.4%/44.2%), leukopenia (39.5%/48.1%), lymphopenia (38.6%/28.8%), neutropenia (37.7%/51.9%), pneumonia (32.5%/17.3%), anemia (26.3%/25.0%), hypokalemia (16.7%/3.8%), and hypertension (10.5%/11.5%). Infusion-related reactions occurred in 36 (31.6%) patients, the majority of which were mild. A total of 5 TEAE-related deaths (D-VMP, n=3; VMP, n=2) were reported. The addition of DARA to VMP significantly improved efficacy in Chinese NDMM patients and showed a safety profile consistent with the global ALCYONE trial. No new safety concerns were identified. These data support the use of D-VMP for the treatment of Chinese NDMM patients.

High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy

Autologous stem cell transplantation in AL amyloidosis: Muddy waters

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial

Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (vcd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study

Subgroup Analyses of Progression-Free Survival from the Phase 3 Octans and Alcyone Studies in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib, Melphalan, and Prednisone with or without Daratumumab

A real‐life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis

Health‐related Quality of Life in Patients with Light Chain Amyloidosis Treated with Bortezomib, Cyclophosphamide, and Dexamethasone ± Daratumumab: Results from the ANDROMEDA Study

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

Renal Transplant Outcomes in Plasma Cell Dyscrasias and AL Amyloidosis after Treatment with Daratumumab

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis

P-163: Efficacy and Safety of Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Chinese Patients with Newly Diagnosed Multiple Myeloma: OCTANS

Combination of Bortezomib in the Induction, Conditioning and Consolidation with Autologous Hematopoietic Stem Cell Transplantation in Patients with Immunoglobulin Light Chain Amyloidosis

Response adaptive salvage treatment with daratumumab–lenalidomide–dexamethasone for newly diagnosed transplant‐eligible multiple myeloma patients failing front‐line bortezomib‐based induction therapy—ALLG MM21

High rate of profound clonal and renal responses with daratumumab treatment in heavily pre‐treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate

Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis

Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA

[Daratumumab for the Treatment of Primary Systemic Amyloidosis: a Multicenter Retrospective Analysis].

Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy